ReviewDialogues in health2026
Mpox and the one health approach.
Review in Dialogues in health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To synthesize updated epidemiological, genomic, clinical, and policy evidence on mpox, with emphasis on the emergence of Clade I sub-lineage "Clade Ib" and its implications for One Health-based preparedness. Methods: This narrative, non-systematic state-of-the-art review draws on literature indexed in PubMed/MEDLINE, Scopus, Web of Science, and Embase, alongside official reports from WHO, Africa CDC, CDC, ECDC, and FAO. Searches covered January 2000 to May 2025, with epidemiological data included through 31 May 2025. Human observational studies, outbreak reports, genomic analyses, clinical trials, and guidance documents were included. Evidence was synthesized in alignment with SANRA principles. Key findings: Since the 2022 global outbreak driven by Clade IIb, mpox epidemiology has shifted with sustained transmission of Clade I variants in Central Africa and the emergence of a proposed Clade Ib lineage characterized by APOBEC3-associated mutational signatures. Pediatric predominance and household transmission patterns distinguish recent outbreaks from earlier sexual-network-associated spread. Vaccine effectiveness of JYNNEOS varies by population and dosing regimen, while randomized trials (PALM007, STOMP) have not demonstrated statistically significant clinical benefit of tecovirimat on primary endpoints. Environmental surveillance and genomic sequencing remain critical to tracking transmission dynamics. Implications: Even amid sustained human-to-human transmission, integrated One Health strategies-linking human, animal, and environmental surveillance are essential for outbreak containment, equitable vaccine deployment, and long-term prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.